UK-based Paragraf is working on a range of diagnostic sensors built using graphene, allowing for faster, more sensitive testing products.
With a broad pipeline focused on neurodegenerative disease, AC Immune is about to begin a Phase II program investigating an alpha-synuclein-targeted peptide vaccine with a diagnostic to stratify patients.
Tapping into the interplay between gut microbiota and an underappreciated subset of T cells could lead to therapies in a range of diseases.
In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.
Utilizing the genetic overlap between frontotemporal dementia and amyotrophic lateral sclerosis, AviadoBio is seeking to develop gene therapies which can stop both these devastating diseases in their tracks using novel delivery techniques.
A selection of articles you might have missed from June 2022, including a deep dive into venture finance, an in depth discussion about Russia's upcoming drug supply woes, and the latest Rising Leaders interviews.
Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.
Flagship products like Dexcom’s G7 and Abbott’s FreeStyle Libre 3 offer currently unrivalled accuracy of blood glucose measurement. However, as truly noninvasive technologies improve, the future basis for these companies’ growth is on shaky ground.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.